As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

The biggest bright spot for As­traZeneca over the last few years has been its work in on­col­o­gy, as CEO Pas­cal So­ri­ot has helped shep­herd block­busters Imfinzi, Lyn­parza, and Calquence, among oth­er can­cer med­i­cines.

One of the top ex­ec­u­tives from the can­cer di­vi­sion is now mak­ing the leap to the larg­er C-suite. The Swedish-British phar­ma named its on­col­o­gy chief de­vel­op­ment of­fi­cer Cris­t­ian Mas­sace­si as the new CMO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.